Cargando…
Multiplex Patient-Based Drug Response Assay in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDA) is an extremely lethal malignancy arising from the pancreas. The treatment of PDA is complicated by ineffective treatments and a lack of biomarkers predictive of treatment success. We have designed a patient-derived organoid (PDO) based high-throughput drug scr...
Autores principales: | Armstrong, Andrew, Haque, Muhammad R., Mirbagheri, Sina, Barlass, Usman, Gilbert, Douglas Z., Amin, Jaimin, Singh, Ajaypal, Naqib, Ankur, Bishehsari, Faraz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301364/ https://www.ncbi.nlm.nih.gov/pubmed/34201419 http://dx.doi.org/10.3390/biomedicines9070705 |
Ejemplares similares
-
Opioid use as a potential risk factor for pancreatic cancer in the United States: An analysis of state and national level databases
por: Barlass, Usman, et al.
Publicado: (2021) -
Marked Elevation of Lipase in COVID-19 Disease: A Cohort Study
por: Barlass, Usman, et al.
Publicado: (2020) -
Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013) -
Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013) -
Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)